The Company

We unlock the potential of the whole genome and transcriptome in cancer

Current approaches that sequence panels of cancer-associated genes have been adopted in clinical practice to guide tailored treatments. However, these tests evaluate a fraction of a cancer's genome and focus only on the most common actionable mutations.

Isabl GxT™ analyzes 100% of the genome and transcriptome to comprehensively identify clinically relevant mutations that were previously inaccessible. Our breakthrough technology provides unprecedented clarity into tumor biology to aid treatment planning. This opens up opportunities for precision diagnostics, disease surveillance and biomarker discovery.